Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 2/20 | 0.78 |
| ▸ | SRC | P12931 | 2/20 | 0.78 |
| ▸ | KDR | P35968 | 2/20 | 0.78 |
| ▸ | IGF1R | P08069 | 2/20 | 0.78 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.78 |
| ▸ | ABL1 | P00519 | 1/20 | 0.78 |
| ▸ | EGFR | P00533 | 1/20 | 0.78 |
| ▸ | INSR | P06213 | 1/20 | 0.78 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.78 |
| ▸ | TNK2 | Q07912 | 13/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
| ▸ | PRKDC | P78527 | 1/20 | 0.50 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.50 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.50 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.50 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593460 | 1.00 | RAF1 (0.78) | RAF1SRCKDRIGF1RPDPK1 | |
| SCHEMBL12165142 | 0.96 | IGF1R (0.75) | RAF1SRCKDRIGF1RPDPK1 | |
| SCHEMBL6942069 | 0.94 | IGF1R (0.76) | RAF1SRCKDRIGF1RPDPK1 | |
| SCHEMBL594880 | 0.90 | RAF1 (0.84) | RAF1SRCKDRIGF1RPDPK1 | |
| SCHEMBL594882 | 0.90 | RAF1 (0.84) | RAF1SRCKDRIGF1RPDPK1 | |
| SCHEMBL6940706 | 0.90 | IGF1R (0.75) | RAF1SRCKDRIGF1RPDPK1 | |
| SCHEMBL593915 | 0.89 | RAF1 (0.74) | RAF1SRCKDRIGF1RPDPK1 | |
| SCHEMBL593913 | 0.89 | RAF1 (0.74) | RAF1SRCKDRIGF1RPDPK1 | |
| SCHEMBL6940393 | 0.89 | IGF1R (0.76) | RAF1SRCKDRIGF1RPDPK1 | |
| SCHEMBL593497 | 0.88 | RAF1 (1.00) | RAF1SRCKDRIGF1RPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2325186-B1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS LLC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8586546-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2385053-B1 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI PHARM INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI Pharmaceuticals, LLC | 2013-06-27 | — | — | US | disclosed |
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | OSI PHARMACEUTICALS, LLC. | 2012-08-16 | — | — | US | disclosed |
| US-8114846-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2385053-A2 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, Inc. (US) | 2011-11-09 | — | — | EP | disclosed |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | OSI Pharmaceuticals, LLC | 2011-09-08 | — | — | US | disclosed |
| US-20110190496-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| US-7943767-B2 | Fused bicyclic mTOR inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-1951724-B1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARM INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | OSI PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| US-7700594-B2 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7651687-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207767-A1 | Combined Treatment with an EGFR Kinase Inhibitor and an Agent that Sensitizes Tumor Cells to the Effects of EGFR Kinase Inhibitors | EGFR, ERBB2, MTOR | RAF1 70/4885SRC 15/4885KDR 112/4885 |
| US-20100099679-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | RAF1 260/4885SRC 294/4885KDR 2434/4885 |
| US-20130165651-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | RAF1 260/4885SRC 294/4885KDR 2434/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | RAF1 537/4885SRC 151/4885KDR 979/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | RAF1 244/4885SRC 12/4885KDR 532/4885 |
| US-20100166776-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN AGENT THAT SENSITIZES TUMOR CELLS TO THE EFFECTS OF EGFR KINASE INHIBITORS | EGFR, ERBB2, RICTOR | RAF1 244/4885SRC 12/4885KDR 532/4885 |
| US-20110190496-A1 | FUSED BICYCLIC mTOR INHIBITORS | MTOR, RICTOR, MAPKAP1 | RAF1 260/4885SRC 294/4885KDR 2434/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | RAF1 88/4885SRC 361/4885KDR 1245/4885 |
| US-20110218183-A1 | Fused Bicyclic mTOR Inhibitors | MTOR, RICTOR, MAPKAP1 | RAF1 260/4885SRC 294/4885KDR 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.